Coordinatore | INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL
Organization address
address: Old Brompton Road 123 contact info |
Nazionalità Coordinatore | United Kingdom [UK] |
Totale costo | 231˙283 € |
EC contributo | 231˙283 € |
Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
Code Call | FP7-PEOPLE-2013-IIF |
Funding Scheme | MC-IIF |
Anno di inizio | 2014 |
Periodo (anno-mese-giorno) | 2014-04-04 - 2016-04-03 |
# | ||||
---|---|---|---|---|
1 |
INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL
Organization address
address: Old Brompton Road 123 contact info |
UK (LONDON) | coordinator | 231˙283.20 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Prostate cancer can be stratified as ETS gene rearranged (ETSR) and non-rearranged (ETSNR), with the latter comprising a heterogeneous group of 50-60% of all cancers. This project will characterize a subgroup of ETSNR cancers that have a CHD1 deletion (CHD1del). Recent sequencing studies have elucidated CHD1- cancers as ETSNR, and commonly PTEN and p53 wildtype and SPOP mutated, comprising up to 26% of all prostate cancers (1). ETSR cancers largely have hormone driven oncogenes that may have prognostic and predictive utility (2, 3). Less is known about ETSNRCHD1del cancers. Their lack of ETS fusions raises concern that these may not be generated through androgen receptor (AR) transcription and are not AR driven. ETSNRCHD1del cancers have a huge excess of somatic intrachromosomal rearrangements (up to 800) compared to ETSR cancers presumably due to a DNA repair defect (1). This is supported by CHD1’s association with the SSRP1, part of the FACT complex, that is implicated in transcriptional regulation and DNA repair (4-9). We hypothesize that CHD1 deleted tumors are less sensitive to endocrine and taxane therapy, have a worse prognosis and need alternative treatment strategies.'
Development of new gene therapy approaches for the treatment of ocular neovascularization
Read More"Discovery Festival 2012 - Science meets nightlife in an innovative festival with live science, cutting edge art and top notch music. For the first time in 3 cities all over the Netherlands."
Read More